Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 12/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2813725 | 0.90 | NR1H2 (0.42) | NR1H2NR1H3 | |
| SCHEMBL30597746 | 0.90 | L3MBTL1 (0.44) | NR1H2ESR2L3MBTL1CA12CA1 | |
| SCHEMBL19013607 | 0.87 | NR1H2 (0.45) | NR1H2AURKACDK2L3MBTL1USP30 | |
| SCHEMBL13173591 | 0.86 | NOD2 (0.46) | NR1H2ESR2CA12CA1CA2 | |
| SCHEMBL29443054 | 0.86 | L3MBTL1 (0.52) | NR1H2AURKACDK2L3MBTL1 | |
| SCHEMBL18989603 | 0.86 | PTGS2 (0.43) | NR1H2AURKACDK2L3MBTL1 | |
| SCHEMBL29632037 | 0.86 | PTGS2 (0.43) | NR1H2AURKACDK2L3MBTL1 | |
| SCHEMBL21490334 | 0.86 | L3MBTL1 (0.52) | NR1H2AURKACDK2L3MBTL1 | |
| SCHEMBL30071461 | 0.86 | USP30 (0.49) | NR1H2AURKACDK2L3MBTL1USP30 | |
| SCHEMBL3371321 | 0.86 | USP30 (0.49) | NR1H2AURKACDK2L3MBTL1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-12-09 | — | — | US | disclosed |
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-12-09 | — | — | US | disclosed |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-11-07 | — | — | US | disclosed |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-11-07 | — | — | US | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2008154271-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | NR1H2 1826/4885ESR2 1780/4885AURKA 4341/4885 |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | SAMHD1, POLRMT, NUDT1 | NR1H2 1873/4885ESR2 3407/4885AURKA 1999/4885 |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | NR1H2 2118/4885ESR2 1594/4885AURKA 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.